Stinging nettle leaf has been used in traditional treatments for conditions such as lower urinary tract symptoms, possibly through a smooth muscle relaxant effect. Monash University scientists have investigated the mechanism in studies in vitro and in vivo. Read More
Preclinical data has been reported for RCD-405, which is being developed by Arcede Pharma, a spin-out from Respiratorius AB, for the treatment of severe asthma and chronic obstructive pulmonary disease (COPD). Read More
There is a need of better markers that reflect key mechanisms involved in diabetic kidney disease (DKD). In a new study, investigators have identified increased concentrations of neuroblastoma suppressor of tumorigenicity 1 (NBL1) as a strong and independent predictor of progression to end-stage kidney disease (ESKD) in patients with diabetes. Read More
Blue Water Vaccines (BWV) will attempt to present monkeypox antigens within its norovirus shell and protrusion (S&P) virus-like particle (VLP) platform to develop a novel monkeypox vaccine. Read More
Brii Biosciences has disclosed prodrugs of 4'-ethynyl-2-fluoro-2'-deoxyadenosine (EFdA) reported to be useful for the treatment of HIV infection. Read More
HiberCell has described eukaryotic translation initiation factor 2-alpha kinase 4 (GCN2) inhibitors reported to be useful for the treatment of cancer, Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis and spinocerebellar ataxia. Read More
The development of cancer after p53 inactivation is determined by a series of genomic changes that occur in four steps. The loss of heterozygosity of TP53 (the gene encoding p53 in humans, named Trp53 in mice) is followed by an accumulation of deletions, genome doubling, and the emergence of gains and amplifications. Read More
Halia Therapeutics has presented serine/threonine-protein kinase Nek7 inhibitors reported to be useful for the treatment of cancer, asthma, obesity, type 2 diabetes, hepatitis, peritonitis, neurodegeneration and psoriasis, among others. Read More
Scripps Research Institute has synthesized dipeptidyl peptidase 4 (DPP4) inhibitors reported to be useful for the treatment of lung diseases. Read More
Staphylococcus aureus is the most common bacterium recovered in orthopedic infections. Exebacase and CF-296 (ContraFect) are known to be anti-staphylococcal lysins with activity against S. aureus. Read More
Jemincare and its wholly owned subsidiary Shanghai Jemincare Pharmaceutical have signed an exclusive worldwide license agreement with Roche and Genentech for the development and commercialization of the androgen receptor degrader JMKX-002992. Read More
